Asset Publisher

angle-left Siham Sabri, PhD

Junior Scientist, RI-MUHC, Glen site

Cancer Research Program

Department of Oncology (main affiliation), Division of Experimental Medicine (Cross-Appointment) McGill CIHR Drug Development Training Program (DDTP): Member and Mentor. McGill Centre for Translational Research in Cancer (MCTRC), Réseau de Recherche sur le Cancer, Axe Thérapies Expérimentales

 

Keywords


brain tumor • tumor invasion • angiogenesis • targeted therapies • biomarkers • proteomics

Research Focus


My research focuses on understanding the mechanisms of increased growth of tumor vessels (angiogenesis) and tumor infiltration (invasion) in Glioblastoma multiforme (GBM). GBM is the most common malignant primary brain tumor in adults and has a devastating outcome. Despite a multimodal treatment combining surgery, radiation therapy and chemotherapy, the median survival rate of patients diagnosed with GBM is approximately 15 months and only five per cent of patients survive more than 5 years. I have established a large research program with my team and several collaborators to translate our findings from the lab to clinical trials and identify biomarkers of response to treatment using a platform of innovative technologies. We will also test new compounds to inhibit tumor angiogenesis and invasion in mice bearing intracranial injections of GBM tumor cells established in my laboratory. This strategy will lead to the implementation of targeted therapies in clinical practice in GBM.

Selected Publications


Click on Pubmed to see my current publications list

  • David Lesniak, Siham Sabri, Yaoxian Xu, Kathryn Graham, Pravin Bhatnagar, Suresh Mavanur and Bassam Abdulkarim. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer. Plos One. 2013 Aug 26;8(8):e71987. doi: 10.1371/journal.pone.0071987.

  • Manik Chahal, Bassam Abdulkarim, Yaoxian Xu, Marie-Christine Guiot, Jacob C. Easaw,Nicolas Stifani and Siham Sabri. O6-Methylguanine-DNA Methyltransferase is a Novel Negative Effector of Invasion in Glioblastoma Multiforme. Molecular Cancer Therapeutics, Nov;11 (11):2440-50. Epub 2012 Sep 17. Impact factor 2012: 5.599. Siham Sabri: corresponding author

  • Bassam Abdulkarim, Julie Cuartero, John Hanson, Jean Deschenes, David Lesniak and Siham Sabri. Increased Risk of Locoregional Recurrence for Women with T1-2N0 Triple Negative Breast Cancer Treated with Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. Journal of Clinical Oncology, 2011 Jul 20; 29(21): 2852-8. Impact factor 2011: 18.372 (4th among 184 oncology journals).

  • Manik Chahal, Yaoxian Xu, David Lesniak, Kathryn Graham, Konrad Famulski, James Christensen, Manish Aghi, Amanda Jacques, David Murray, Siham Sabri* and Bassam Abdulkarim*. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib, Neuro-oncology 2010 Aug; 12(8): 822-33. Epub 2010 Feb 23]. Impact factor: 5.723; *Siham Sabri and Bassam Abdulkarim contributed equally to this work. * Siham Sabri and Bassam Abdulkarim: corresponding authors.

  • David Lesniak, Thoms John, Jean Deschenes, Raymond Lai, John Thoms, David Murray, Sunita Gosh, John Mackey, Siham Sabri*, and Bassam Abdulkarim*. Overexpression of b1 integrin decreases trastuzumab sensitivity and predicts trastuzumab resistance in HER-2-positive breast cancer patients. Cancer Research 2009; 69: (22). Nov. 15, 2009: 8620- 8628. Impact factor: 7.856; *Siham Sabri and Bassam Abdulkarim contributed equally to this work